Krishna Institute of Medical Sciences Ltd (KIMS) Q1 FY26: ₹872 Cr Revenue, ₹79 Cr PAT, P/E 82x – Hospitals or Hospitality Scam Pricing?
1. At a Glance
KIMS Hospitals is the healthcare thali of Andhra and Telangana – 4,800+ beds, 40+ specialties, and a P/E ratio so high (82x) it could give Apollo itself a cardiac scare. Q1 FY26 revenue ₹872 crore (+27% YoY), PAT ₹78.6 crore (-9% YoY). Occupancy just 52% – meaning half their beds are for show, like props in a TV serial. Promoters hold 34%, debt is rising (₹2,557 crore) thanks to aggressive 2,000+ bed expansion. Dalal Street, meanwhile, is paying premium hotel prices for a hospital still struggling with occupancy.
2. Introduction
Once upon a time (1973), Krishna Institute of Medical Sciences was a modest regional hospital. Today, it’s a 30,000-crore market cap beast, opening hospitals like pan shops in every tier-2 and tier-3 city it can find.
KIMS specializes in “affordable corporate healthcare” – oxymoron much? It thrives on cardiac, ortho, neuro, mother & child, renal, oncology, and now… expansion fever. With 2,500+ new beds planned across Bangalore, Mumbai (Thane), AP, and Telangana, it wants to double capacity by FY27.
But here’s the irony: while expanding at breakneck speed, occupancy sits at 52%. Imagine buying a second house while leaving your first one half-empty. On top of that, 90% of revenue still comes from AP/Telangana. Expansion into Maharashtra, Kerala, Karnataka is work-in-progress – so for now, it’s still a “regional superpower,” not a national champion.
Oh, and let’s not forget the spice: trademark disputes (others also use KIMS brand), ₹307 crore tax notice, and promoter stake drop by 5%. Hospitals may save lives, but investors need life support after reading this fine print.
3. Business Model – WTF Do They Even Do?
Hospitals sound fancy, but it’s basically a hotel with extra machines and nurses:
Core Service: Multispecialty healthcare (40+ specialties). They sell surgeries, treatments, and hope – packaged with AC wards.
Clusters:
Telangana = 73% revenue, EBITDA machine.
Andhra Pradesh = 24%, steady but less profitable.
Maharashtra = 3%, still testing waters.
Revenue Mix (9MFY25):
Cardiac Sciences 17%
Ortho 14%
Neuro 10%
Mother & Child 10%
Gastric + Renal ~18%
Oncology 6%
Others 22%
Payor mix is juicy: 53% cash, 28% insurance, 13% corporate, 6% Aarogyasri (Govt. scheme). Basically, half their patients pay upfront – no insurance drama. Doctors love it, patients… not so much.
